



# Bringing Together Canada's Cardiovascular-Focused Guidelines

## 4th ANNUAL CHEP+ CONFERENCE

April 9 - 14, 2022 (Virtual)

Program Agenda



# 4th Annual CHEP+ Conference 2022

2022 Conference Co-Chairs | 2022 C-CHANGE Guideline Co-Chairs



**Dr. Sheldon Tobe MD,**  
FRCP, MScCH (HPTE),  
FACP, FAHA



**Dr. Rahul Jain MD,**  
CCFP, MScCH (HPTE)

## Full-Day Conference - Saturday, April 9, 2022

We are pleased to host the **4th Annual CHEP+ Conference for 2022 Update of the C-CHANGE Clinical Practice Guideline (online)**. This interactive and practical program is designed for family physicians, specialists, nurse practitioners, nurses, pharmacists, dietitians and other health care practitioners with an interest in cardiovascular disease prevention and management.

This year's conference is devoted to bringing together the latest updates and clinical pearls from Canada's cardiovascular-focused guidelines, including Hypertension, Diabetes, Lipids, Obesity, Stroke, Atrial Fibrillation, Heart Failure, Cardiac Rehabilitation, and many others with discussions on the latest clinical trial results and challenges facing the care of multi-morbidity patients with complex conditions.

## Concurrent Workshops - April 11 - 14, 2022

The concurrent workshops are designed to support clinicians on how to implement the C-CHANGE guideline updates in their practice. The workshops are 1hr case-based interactive group sessions (40 min of presentation with questions throughout the case module to stimulate discussion, and 20 min for Q+A). Delegates can choose topic areas.

## Overall Program Objectives

At the conclusion of this program, participants will be able to:

1. Describe the 2022 updates to the C-CHANGE Guideline
2. Develop an approach to the multi-comorbid patient
3. Summarize the newest and emerging therapies and how they apply to renal and cardiovascular protection

**Full-Day Conference:** Applications to respective accreditation bodies have been submitted.

**Concurrent workshops:** This 3 credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 3.00 Mainpro+ credits.

## Register Today!

**Early Bird** - (Ends January 31, 2022)

- Conference only: **\$90.00**
- Conference + Concurrent Workshops: **\$99.00**

**Regular Pricing**

- Conference only: **\$125.00**
- Conference + Concurrent Workshops: **\$150.00**

For more info: [www.chepplus.com](http://www.chepplus.com)



Scan QR Code for Tickets  
or click [here](#)

## Conference Speakers

### Plenary Speakers

Speakers are committee members of the 2022 C-CHANGE Guideline Panel and will present updates from their respective C-CHANGE Guideline Groups

- **Alexandre Poppe**, MD, CM, FRCPC

Stroke Neurologist, Centre Hospitalier de l'Université de Montréal (CHUM),  
Clinical Associate Professor, Department of Neurosciences, Université de Montréal

- **Harpreet S. Bajaj**, MD, MPH, ECNU, FACE

Endocrinologist and Director of Late-Phase Research, LMC Healthcare, Canada  
Research Associate, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto  
Chair, Clinical Practice Guidelines, Diabetes Canada

- **Sean Wharton**, MD, PharmD, FRCP(C)

Internal Medicine Specialist, Women's College Hospital, Medical Director, Wharton Medical  
Clinic, Hamilton Health Sciences Centre, Adjunct Professor, McMaster University and York  
University

- **Simon Bacon**, PhD, FTOS, FCCS, FABMR

Co-Director, Montreal Behavioural Medicine Centre, CIUSSS-NIM, Hopital du Sacre-Coeur de  
Montreal, Professor, Department of Health, Kinesiology, and Applied Physiology, Concordia  
University

- **Glen Pearson**, BScPhm, PharmD, FCSHP, FCCS

Co-Director, Cardiac Transplant Clinic Chair, Trainee Research Access Committee (TRAC)  
Professor of Medicine, Division of Cardiology, University of Alberta, Mazankowski Alberta  
Heart Institute

- **George Thanassoulis**, MD MSc FRCP(C)

Director, Preventive and Genomic Cardiology, FRQ-S Clinician-Scientist/Chercheur-  
Boursier Clinicien, Associate Professor of Medicine, McGill University

## Conference Speakers

### Plenary Speakers

- **Laurent Macle** MD, FRCP(C), FHRS

Cardiologue-Électrophysiologiste, Professeur titulaire de Médecine, Université de Montréal

- **Jason Andrade** MD, FRCPC, FHRS

Associate Professor of Medicine at UBC, Adjunct Professor at Université de Montréal

Director, VGH Cardiac Electrophysiology Laboratory, Co-Chair of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines

- **Sean Virani** MD, MSc, MPH, FRCPC, FCCS /

Head, Division of Cardiology, Providence Health Care, Physician Program Director, The

HEART Centre, St. Paul's Hospital, Provincial Medical Director, Cardiac Services BC

Associate Professor, Department of Medicine, University of British Columbia,

Past-President, Canadian Heart Failure Society

- **Michael McDonald** MD, FRCPC

Cardiologist, University Health Network, Toronto, Assistant Professor, University of Toronto

- **Doreen M. Rabi** MD, MSc, FRCPC

Head, Division of Endocrinology & Metabolism, Deputy Head (Academic), Department of

Medicine, Professor in the Departments of Medicine, Community Health and Cardiac Sciences, University of Calgary

- **Eric E. Smith**, MD, MPH, FRCPC, FAHA

Professor of Neurology, Katthy Taylor Chair in Vascular Dementia, Cumming School of

Medicine, University of Calgary

- **Rahul Jain** MD, CCFP, MScCH (HPTE)

Family Physician and Hospitalist, Sunnybrook Health Sciences Centre,

Assistant Professor, Department of Family and Community Medicine, University of Toronto.

- **Peter Liu** MD, FRCPC

Cardiologist, Chief Scientific Officer/ Vice-President, Research, Director Cardiac Function

Laboratory, University of Ottawa Heart Institute Professor, Faculty of Medicine, University of Ottawa

- **James Stone** MD, FRCPC

Clinical Professor, Cardiac Sciences, Medicine, University of Calgary

## Program Agenda | Conference

### Saturday April 9th, 2022

8:45 - 9:00	• Introductions   Dr. Sheldon Tobe, Dr. Rahul Jain, Ms. Diane Hua-Stewart
9:00 - 9:20	<b>P1.</b> What's New in Stroke Best Practices?   Dr. Alexandre Poppe
9:20 - 9:40	<b>P2.</b> Implementing the New Diabetes Guideline   Dr. Harpreet Bajaj
9:40 - 10:00	<b>P3.</b> Practice Pearls from the New Obesity Guideline   Dr. Sean Wharton
10:00 - 10:20	<b>Q&amp;A with Panel   Moderator: Dr. Rahul Jain</b>

### 10:20 - 10:50 | EXHIBITOR SHOWCASE

10:50 - 11:10	<b>P4.</b> What's New in Cardiac Rehab?   Dr. Simon Bacon
11:10 - 11:30	<b>P5.</b> Implementing the New CCS Lipid Guideline   Dr. Glen Pearson, Dr. George Thanssoulis
11:30 - 11:50	<b>P6.</b> What's New in Atrial Fibrillation?   Dr. Laurent Macle/Dr. Jason Andrade
11:50 - 12:10	<b>Q&amp;A with Panel   Moderator Dr. Peter Liu</b>

### 12:10 - 12:30 | EXHIBITOR SHOWCASE

12:30 - 12:50	<b>P7.</b> Implementing the New CCS Heart Failure Guideline   Dr. Sean Virani, Dr. Michael McDonald
12:50 - 1:10	<b>P8.</b> What's New in Hypertension?   Dr. Doreen Rabi
1:10 - 1:30	<b>P9.</b> Translating the New Dementia Guideline for Primary Care   Dr. Eric Smith
1:30 - 1:50	<b>Q&amp;A with Panel   Moderator: Dr. James Stone</b>
1:50 - 2:00	<b>Final Remarks   Dr. Rahul Jain</b>

### 2:00 - 3:00 | EXHIBITOR SHOWCASE

## Program Agenda | Concurrent Workshops

### Monday April 11th, 2022 | 7:00 - 9:00 PM ET

- 7:00 - 8:00 | **A1. CV Risk Reduction in T2DM - SGLT2i/GLP1 in Patients with DM and CVD** Facilitator: Dr. Sol Stern | Moderator: Dr. Peter Liu
- 7:00 - 8:00 | **A2. Blood Pressure Measurement Diagnosis and Follow-Up of Hypertension** Facilitator: Dr. Rahul Jain | Moderator: Dr. Gemma Cheng
- 8:00 - 9:00 | **A3. Cardiovascular Management of Patients with Chronic Kidney Disease** Facilitator: Dr. Sheldon Tobe | Moderator: Ms. Thuy Pham
- 8:00 - 9:00 | **A4. Anticoagulation in Nonvalvular Atrial Fibrillation in Patients with Renal Disease** Facilitator: Dr. Jeffrey Habert | Moderator: Dr. Rahul Jain

### Tuesday April 12th, 2022 | 7:00 - 9:00 PM ET

- 7:00 - 8:00 | **B1. Blood Pressure Management in Patients with Chronic Kidney Disease** Facilitator: Dr. Sheldon Tobe | Moderator: Dr. Rahul Jain
- 7:00 - 8:00 | **B2. CV Risk Reduction in T2DM - SGLT2i/GLP1 in Patients with DM and CVD** Facilitator: Dr. Subodh Verma | Moderator: Dr. Sol Stern
- 8:00 - 9:00 | **B3. Anticoagulation in Nonvalvular Atrial Fibrillation in Patients with Renal Disease** Facilitator: Dr. Jeffrey Habert | Moderator: Dr. Kristin Terenzi
- 8:00 - 9:00 | **B4. Blood Pressure Measurement Diagnosis and Follow-Up of Hypertension** Facilitator: Dr. Lisa Dubrofsky | Moderator: Dr. Jonathan Gabor

### Wednesday April 13th, 2022 | 7:00 - 9:00 PM ET

- 7:00 - 8:00 | **C1. Renal Protection in Patients with Diabetes and Advanced Nephropathy** Facilitator: Dr. Jonathan Gabor | Moderator Dr. Darlene Kitty
- 7:00 - 8:00 | **C2. Blood Pressure Management in Patients with Chronic Kidney Disease** Facilitator: Dr. Lisa Dubrofsky | Moderator: Dr. Kristin Terenzi

8:00 - 9:00	<p><b>C3. SGLT2i for Cardiac Protection in Patients with Heart Failure</b> Facilitator Dr. Richard Choi   Moderator: Dr. Sol Stern</p>
8:00 - 9:00	<p><b>C4. Blood Pressure Measurement Diagnosis and Follow-Up of Hypertension</b> Facilitator: Dr. Rahul Jain   Moderator: Dr. David Dannenbaum</p>

**Thursday April 14th, 2022 | 7:00 - 9:00 PM ET**

7:00 - 8:00	<p><b>D1. How C-CHANGE can Help Management of the Multi Co-Morbidity Patient</b> Facilitator: Dr. Rahul Jain   Moderator: Ms. Thuy Pham</p>
7:00 - 8:00	<p><b>D2. CV Risk Reduction in T2DM - SGLT2i/GLP1 in Patients with DM and CVD</b> Facilitator: Dr. Subodh Verma   Moderator: Dr. Sol Stern</p>
8:00 - 9:00	<p><b>D3. Cardiovascular Management of Patients with Chronic Kidney Disease</b> Facilitator: Dr. Richard Choi   Moderator: Dr. Jonathan Gabor</p>
8:00 - 9:00	<p><b>D4. Global Cardiovascular Risk Assessment and Risk Reduction Women with Hypertension</b> Facilitator: Dr. James Stone   Moderator: Dr. Gemma Cheng</p>

**CONCURRENT WORKSHOPS:** This 3 credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario Chapter for up to 3.00 Mainpro+ credits.

**CHOOSE 8 WORKSHOPS:** choose from a variety of CVD-focused topic areas.

- Each concurrent workshop is 1hr case-based interactive group sessions (40 min of presentation with questions throughout the case module and 20 min for Q+A).
- Each workshop requires completion of a brief online pre and post-session survey.

## Concurrent Workshop | Facilitators

**Sol Stern, MD, MSc, MCFP**  
Family Physician and CME Educator,  
Argus Medical Centre,  
Oakville, Ontario

**Peter Liu, MD, FRCPC**  
Cardiologist, Chief Scientific Officer/ Vice-  
President, Research, Director Cardiac Function  
Laboratory, University of Ottawa Heart Institute  
Professor, Faculty of Medicine, University of  
Ottawa

**Sheldon Tobe, MD, FRCPC, MScCH (HPTE),  
FACP, FAHA**, Sunnybrook Health Sciences  
Centre, Professor, Faculty of Medicine, University  
of Toronto and Northern Ontario School of  
Medicine.

**Rahul Jain, MD, CCFP, MScCH (HPTE)**  
Family Physician and Hospitalist,  
Sunnybrook Health Sciences Centre,  
Assistant Professor, Department of Family and  
Community Medicine, University of Toronto.

## Concurrent Workshop | Facilitators

**Thuy Pham, RN(EC), MN, MScCH**  
Nurse Practitioner, Division of Nephrology,  
Sunnybrook Health Sciences Centre  
Adjunct Lecturer, Faculty of Nursing, University  
of Toronto

**Lisa Dubrofsky, MDCM, FRCPC, FASH**  
Nephrologist and Hypertension Specialist,  
Sunnybrook Health Sciences Centre and  
Women's College Hospital  
Clinical Associate, Division of Nephrology,  
University of Toronto

**James Stone MD, FRCPC**  
Clinical Professor, Cardiac Sciences, Medicine,  
University of Calgary

**Kristin Terenzi, MD, CCFP**  
Family Physician, C-CHANGE Guideline Panel  
Member

**David Dannenbaum, MD, CCFP**  
Faculty Lecturer, Family Medicine  
Medicine, McGill University

**Darlene Kitty, MD, CCFP**  
Director of the MD Indigenous Program at the  
University of Ottawa Faculty of Medicine  
Assistant Professor, Department of Family  
Medicine, University of Ottawa

**Jonathan Gabor, MSc, MD, FRCPC, SCH, Dip.**  
ABOM Internist and Hypertension Specialist,  
Department of Medicine, Concordia General  
Hospital, Winnipeg, Manitoba

**Richard Choi, MD, FRCPC**  
Cardiologist, St. Joseph's Health Centre/  
Unity Health Toronto, Clinical adjunct  
faculty/Lecturer, Department of Medicine,  
University of Toronto

**Subodh Verma MD, PhD, FRCSC, FAHA**  
Cardiac Surgeon, St. Michael's Hospital, Unity  
Health Toronto, Toronto, ON Scientist, Keenan  
Research Centre for Biomedical Science and Li  
Ka Shing Knowledge Institute of Unity Health  
Canada Research Chair in Cardiovascular  
Surgery

**Gemma Cheng, MD FRCP FRCPC**  
Faculty Member, Family Medicine, McGill  
University

**Jeffrey Habert, MD, CCFP, FCFP**  
Assistant Professor, Department of Family and  
Community Medicine at the University of  
Toronto, Co-Chair of Clinical Guidelines  
Committee Thrombosis Canada



## Concurrent Workshops | Descriptions

### **SGLT2i for Cardiac Protection in Patients with Heart Failure**

Upon completion of this case study, participants should be able to:

- Describe heart failure and its consequences
- Explain the rationale for the management of heart failure to include SGLT2i and the potential benefits
- Describe how and when to introduce SGLT2i for heart failure

### **Global CV Risk Assessment and Risk Reduction Women with Hypertension**

Upon completion of this activity, participants should be able to:

- Do a critical appraisal of CV risk assessment
- Evaluate indications and limitations of CV risk stratification
- Calculate vascular age; discuss how vascular age assessment can help in CV risk reduction
- Formulate a management plan using the Hypertension Canada recommendations

### **Blood Pressure Measurement Diagnosis and Follow-Up of Hypertension**

Upon completion of this case study, participants should be able to:

- Describe the new Hypertension Canada recommendations and algorithm for the diagnosis of hypertension
- Outline the rationale for and the methods for using automated office blood pressure measurements.
- Define White Coat Hypertension, Masked Hypertension, and Masked Uncontrolled Hypertension (MUCH)
- Describe tools for helping learners acquire and teach the knowledge and skills for blood pressure measurement.

### **How C-CHANGE can Help Management of the multi co-morbidity patient**

Upon completion of this activity, participants will be able to:

- Identify recommendations for multiple morbidities from the C-CHANGE guidelines
- Implement recommendations for multiple morbidities in a single patient
- Use the C-CHANGE recommendations to help keep the elderly living at home longer and healthier

### **Anticoagulation in Nonvalvular Atrial Fibrillation in Patients with Renal Disease**

Upon completion of this activity, participants should be able to:

- Describe the rational for anticoagulation of non-valvular atrial fibrillation
- Describe the effect on outcomes of non-valvular atrial fibrillation with CKD
- Describe the management of patients with CKD and non-valvular atrial fibrillation

## Concurrent Workshops | Descriptions

### **Cardiovascular Management of Patients with Chronic Kidney Disease**

Upon completion of this activity, participants should be able to:

- Identify a patient with chronic kidney disease.
- Formulate a treatment plan for cardiovascular risk reduction using the C-CHANGE guidelines including BP control and lipid management.
- Communicate and initiate the treatment plan to reduce cardiovascular risk in patients with chronic kidney disease

### **CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP1-RA receptor agonists in patients with DM and ASCVD)**

Upon completion of this case study, participants should be able to:

- Describe the patient who should be treated with an SGLT2i or GLP-1 RA
- Explain the rationale for this treatment and the potential benefits
- Describe the steps for initiating and monitoring therapy for patients with diabetes

### **Renal Protection in Patients with Diabetes and Advanced Nephropathy**

Upon completion of this activity, participants should be able to:

- Describe advanced diabetic nephropathy and its consequences
- Explain the rationale for the management of advanced nephropathy and the potential benefits
- Describe how advanced nephropathy might be prevented

### **Blood Pressure Management in Patients with Chronic Kidney Disease**

Upon completion of this activity, participants should be able to:

- Describe how to measure blood pressure to inform treatment decisions
- Describe healthy behaviours, for patients with CKD and hypertension, with a focus on sodium intake and physical activity
- Describe an approach and the rationale for the new lower blood pressure target in patients with CKD
- Contrast the strength of evidence for prescribing renin-angiotensin-system inhibitors (RASi) for people with hypertension and CKD with and without proteinuria, with and without diabetes

**FOR INQUIRIES CONTACT:**

diane@chepplus.com

www.chepplus.com